Momenta Pharmaceuticals, Inc.
May 3, 2012

Momenta Pharmaceuticals Reports First Quarter 2012 Financial Results

Phase 1/2 Proof-of-Concept Trial for Novel Oncology Drug Candidate, M402, Initiated; Patient Screening Underway at Trial Sites in the U.S.

CAMBRIDGE, Mass., May 3, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2012.

For the first quarter of 2012, the company reported a net loss of $5.0 million, or ($0.10) per share, compared to a net income of $57.0 million, or $1.13 per diluted share, for the same period in 2011. At March 31, 2012, the company had cash, cash equivalents, and marketable securities of $382.3 million, compared to $348.4 million at December 31, 2011.

"Thanks to the success of enoxaparin we have a strong balance sheet to support our business as we invest in our generic Copaxone® program, our new follow-on biologics collaboration with Baxter, and our emerging novel drug portfolio," said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "Although competition for generic enoxaparin has reduced the revenue we receive for the product, it continues to be an important source of cash flow for the company. Our innovative technology platform that we developed over the last decade provides a strong foundation for future advances that we believe will drive value for the company, cost savings for the healthcare system and significant benefit for our shareholders."

First Quarter Highlights and Recent Progress
Complex Generics Program:
Enoxaparin sodium injection program update

Follow-on Biologics Program:
Baxter collaboration effective

Novel Drug Program:
Productivity in research and development programs

First Quarter 2012 Financial Results

Total revenue for the first quarter of 2012 was $24.2 million (including product revenue of $22.0 million), compared to $78.2 million (including product revenue of $75.8 million) for the same period in 2011. The decrease in revenue was principally driven by a decrease in enoxaparin product revenues following the September 2011 approval and January 2012 launch of a competitor's generic Lovenox. As a result, in January 2012, the company's product revenues earned on net sales of enoxaparin by Sandoz transitioned to a tiered royalty from a hybrid profit share/royalty agreement. Sandoz reported first quarter enoxaparin net sales of $176 million, which was down from $247 million for the first quarter 2011 due to loss of enoxaparin exclusivity. First quarter 2012 revenues also include $0.6 million in amortization of the $33 million payment received from the Baxter collaboration.

Research and development expenses for the first quarter of 2012 were $18.6 million, compared to $12.9 million for the same period in 2011. The increase was primarily due to increased headcount, laboratory and facility expenses to advance the company's development pipeline of complex generics, follow-on biologics, and novel drug candidates.

General and administrative expenses for the quarter ended March 31, 2012 were $11.0 million, compared with $8.3 million for the same period in 2011. The increase is primarily due to an increase of $1.3 million in legal expenses related to enoxaparin litigation, an increase of $1.0 million in stock-based compensation expense, as well as an increase of $1.0 million of personnel and facilities-related expenses, offset by a decrease of $0.8 million in enoxaparin related royalty expense.

At March 31, 2012, Momenta had $382.3 million in cash, cash equivalents and marketable securities. This cash position excludes restricted cash of $17.5 million, which serves as collateral for a security bond related to enoxaparin legal proceedings.

Financial Guidance

Momenta is today reiterating its guidance provided on February 9, 2012 for total operating expenses, excluding stock compensation and royalties payable to the Massachusetts Institute of Technology, and net of collaborative revenues, of approximately $22 to $28 million per quarter for 2012.

Conference Call Information

Management will host a conference call today, May 3, 2012 at 10:00 am EDT to discuss these results and provide an update on the company.  To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 72247825. A replay of the call will be available approximately two hours after the conclusion of the call and will be accessible through May 9, 2012.  To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the access code 72247825.

A live audio webcast of the call will be available on the "Investors" section of the company's web site, www.momentapharma.com.  Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta web site approximately two hours after the call and will be available through May 17, 2012.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, follow-on biologics and to the discovery and development of novel drugs.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, the Company's revenue, expenses and other results of operations, including the quarter ended March 31, 2012, our profitability, our expected product development milestones, our plans for future research and development investment, and our other product development plans and expectations may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the company's Annual Report on Form 10-K for year ended December 31, 2011 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission.  As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein.  Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

 
MOMENTA PHARMACEUTICALS, INC.
Unaudited, Condensed Consolidated Balance Sheets
(in thousands)
     
  March 31, December 31,
  2012 2011
Assets
Cash and marketable securities $ 382,261 $ 348,438
Accounts receivable 22,372 28,171
Restricted cash 17,500 17,500
Other assets 32,333 26,800
Total assets $ 454,466 $ 420,909
Liabilities and Stockholders' Equity
Current liabilities $ 22,625 $ 16,028
Deferred revenue, net of current portion 29,518 1,608
Other liabilities 131 195
Stockholders' equity 402,192 403,078
Total liabilities and stockholders' equity $ 454,466 $ 420,909
     
     
MOMENTA PHARMACEUTICALS, INC.
Unaudited Condensed Statements of Comprehensive (Loss) Income
(in thousands, except per share amounts)
     
  Three Months
  Ended March 31,
  2012 2011
Collaboration revenues:    
Product revenue $ 22,029 $ 75,761
Research and development revenue 2,199 2,411
Total collaboration revenue 24,228 78,172
Operating expenses:    
Research and development* 18,562 12,943
General and administrative* 10,955 8,310
Total operating expenses 29,517 21,253
     
Operating (loss) income (5,289) 56,919
     
Other income (expense):    
Interest income 307 128
Interest expense (41)
Total other income  307 87
     
Net (loss) income  $ (4,982) $ 57,006
     
Comprehensive (loss) income  $ (4,875) $ 56,953
     
Net (loss) income per share:    
Basic $ (0.10) $ 1.15
Diluted $ (0.10) $ 1.13
     
Weighted average shares outstanding:    
Basic 50,240 49,532
Diluted 50,240 50,334
*Includes the following share-based compensation expense:
Research and development $ 1,355 $ 837
General and administrative $ 1,899 $ 929
CONTACT: Lora Pike

         Momenta Pharmaceuticals, Inc.

         lpike@momentapharma.com

         (617) 395-5189
Source: Momenta Pharmaceuticals

News Provided by Acquire Media